摘要
目的检测趋化因子12(C-X-C chemokine ligand 12,CXCL12)及其特异性受体CXCR7在乳腺癌组织中的表达,探讨其与临床病理参数及骨转移的关系。方法采用RT-PCR、组织芯片及免疫组化PV-6000法检测CXCL12、CXCR7在乳腺癌组织及正常组织中的表达,分析其与临床病理参数的关系。结果乳腺癌组织中CXCL12、CXCR7蛋白阳性率分别为73.02%、65.87%,明显高于正常乳腺组织(20.63%、22.22%,P<0.05);其中淋巴结转移组CXCL12、CXCR7阳性率分别为80.59%、76.12%,无淋巴结转移组阳性率分别为64.40%、54.23%,差异具有统计学意义(P<0.05);RT-PCR检测结果证实CXCL12、CXCR7在淋巴结转移组中高表达,CXCR7高表达与乳腺癌骨转移有关。CXCL12、CXCR7表达与乳腺癌淋巴结转移有关(P<0.05),与患者年龄、肿瘤大小、分化程度等无关(P>0.05)。结论 CXCL12、CXCR7高表达与乳腺癌淋巴结转移密切相关,CXCR7高表达与乳腺癌骨转移有关,选择性阻断CXCR7的作用对控制乳腺癌骨转移可能有一定价值。
Purpose To examine the expression of chemokine CXCL12 and its receptor CXCR7 in breast carcinoma, and to evaluate the relationship between their expression and the clinicopatholog factors, as well as bone metastasis. Methods CXCL12 and CXCR7 were detected by RT-PCR and immunohistochemistry and tissue microarrays in normal breast tissue and breast carcinoma tissue. Their relationship with clinicopathological parameters was also analyzed. Results CXCL12 and CXCR7 were detected in both breast carcino- mas tissues and normal tissues, but the expression level of CXCL12 and CXCR7 were found up-regulated in breast carcinomas tissues （73.02% , 65. 870/0 ） as compared with normal tissues （20. 63% , 22.22%0 , P 〈0. 05）. The CXCL12 and CXCR7 expression rate was significantly higher in the positive lymph node metastasis group （80. 59% , 76. 12% ） as compared to that in the negative lymph node metastasis group （64. 40%, 54. 23% ） （P 〈0. 05）. RT-PCR also confirmed the presence of positive CXCL12 and CXCR7 ex- pression in the lymph node metastasis group. The positive expression of CXCR7 was correlated with bone metastasis. The expression level of CXCL12 and CXCR7 correlated well with lymph node metastasis （P 〈 0. 05 ）. However, no relationship can be established be- tween the CXCL12 and CXCR7 expression level and patients＇ age, tumor size, tumor differentiation （ P 〉 0. 05 ）. Conclusion The expression level of CXCL12 and CXCR7 is closely associated with lymph node metastasis of breast carcinomas. The expression level of CXCR7 is associated with bone metastasis. The selectively inhibiting CXCR7 overexpression may be an effective approach to control bone metastasis of breast carcinomas.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2013年第9期961-965,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
甘肃省科技厅科技支撑计划(1011FKCA094)
